drug potency

drug potency

the amount of drug required to produce a given percentage of its maximal effect, irrespective of the size of maximal effect. A drug can have high potency but poor efficacy, meaning that response is seen at very low doses and remains small even at high doses. Drug potency is seldom an important clinical consideration.
Mentioned in ?
References in periodicals archive ?
Objective: The objective of the overall innovation project is to develop a novel instrument to measure and control pharmaceutical drug potency during manufacture at sub-second analysis speeds.
While drug potency has certainly increased in recent decades, the idea that marijuana is similar to other Schedule I drugs or that users regularly experience hallucinations is laughable.
Dennis Grab at The Johns Hopkins University School of Medicine's Department of Pathology, revealed that two MAC drugs, DP-b99 and DP-460, were effective against these parasites and drug potency was maintained for at least 24 h.
The MBP investigated a dozen additional complaints, issued four advisory letters and reprimands, and entered into a consent agreement with NECC to resolve numerous problems related to the misfiling of prescriptions and problems with drug potency and sterility that had previously led to patient infections.
They observed a dramatic decline in the drug potency over that period.
To identify residues involved in inhibitor binding to SERT, we are investigating species-specific differences in drug potency between the evolutionarily divergent human (hSERT) and C.
Breast cancer, one of the leading causes of cancer-related death in women, has presented limited treatment options due to several factors including associated toxicity and a lack of sustained drug potency.
Drug potency typically begins degrading once the drugs are mixed with diluent.
Acetylon's next-generation HDAC6 inhibitor program is focused on enhancing drug potency and reducing or eliminating side effects common to HDAC inhibition through highly selective targeting of the HDAC6 enzyme.
The new demands on formulation and delivery also include packaging and delivering biologics, increasing drug potency and half-life, and greater targeting accuracy.
These Oncology studies show for instance manual versus robotic comparisons in drug potency and patient side effects, $7 per dose direct variable cost savings in consumables, 75% reduction in pharmacist review and approval time, and decreases of 12% to 0.
Acetylon's lead HDAC6 inhibitor program is focused on enhancing drug potency and reducing or eliminating side effects common to HDAC inhibition through highly selective targeting of the HDAC6 enzyme.